Compare Stocks → top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (From Traders Agency) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CBAYNASDAQ:CHMANASDAQ:CNCENASDAQ:HOOKNASDAQ:PRQR Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCBAYCymaBay Therapeutics$32.48$32.39$7.26▼$32.50$3.73B0.324.11 million shs73 shsCHMAChiasma$3.76$4.01$2.77▼$5.74$217.68M1.282.12 million shs147 shsCNCEConcert Pharmaceuticals$8.37$8.37$2.66▼$8.55$401.26M0.522.97 million shsN/AHOOKHookipa Pharma$0.85+10.4%$0.74$0.41▼$2.05$75.70M1.02574,477 shs10.42 million shsPRQRProQR Therapeutics$2.01-0.5%$2.14$1.11▼$3.29$164.34M0.21151,161 shs36,411 shs7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCBAYCymaBay Therapeutics0.00%0.00%0.00%+44.61%+229.08%CHMAChiasma0.00%0.00%0.00%0.00%0.00%CNCEConcert Pharmaceuticals0.00%0.00%0.00%0.00%0.00%HOOKHookipa Pharma+11.11%+11.48%+20.98%+19.72%-10.62%PRQRProQR Therapeutics-0.50%+5.79%-15.90%-3.83%-9.46%top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution…MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCBAYCymaBay Therapeutics0.939 of 5 stars2.00.00.04.70.02.50.6CHMAChiasmaN/AN/AN/AN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AHOOKHookipa Pharma3.6113 of 5 stars3.55.00.00.03.71.71.3PRQRProQR Therapeutics1.4735 of 5 stars3.54.00.00.01.90.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideCHMAChiasmaN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AHOOKHookipa Pharma3.00Buy$5.17507.84% UpsidePRQRProQR Therapeutics3.00Buy$3.6079.10% UpsideCurrent Analyst RatingsLatest CHMA, PRQR, CBAY, CNCE, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/18/2024PRQRProQR TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$1.80 ➝ $2.003/25/2024HOOKHookipa PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$5.003/25/2024HOOKHookipa PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.503/14/2024PRQRProQR TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$2.00 ➝ $2.503/14/2024PRQRProQR TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.002/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59CHMAChiasma$1.11M196.11N/AN/A$1.59 per share2.36CNCEConcert Pharmaceuticals$32.58M12.32N/AN/A$3.24 per share2.58HOOKHookipa Pharma$20.13M4.18N/AN/A$0.91 per share0.93PRQRProQR Therapeutics$7.05M23.20N/AN/A$0.55 per share3.65Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)CHMAChiasma-$74.78M-$1.43N/AN/AN/AN/A-113.57%-57.62%N/ACNCEConcert Pharmaceuticals-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/AHOOKHookipa Pharma-$81.58M-$0.88N/AN/AN/A-405.28%-72.30%-40.51%5/9/2024 (Estimated)PRQRProQR Therapeutics-$30.43M-$0.39N/AN/AN/A-431.65%-56.71%-19.15%5/21/2024 (Estimated)Latest CHMA, PRQR, CBAY, CNCE, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/22/2024Q4 2023HOOKHookipa Pharma-$0.20-$0.11+$0.09N/A$3.60 million$7.41 million3/13/2024Q4 2023PRQRProQR Therapeutics-$0.08-$0.08N/A-$0.08$27.88 million$3.54 million2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCBAYCymaBay TherapeuticsN/AN/AN/AN/AN/ACHMAChiasmaN/AN/AN/AN/AN/ACNCEConcert PharmaceuticalsN/AN/AN/AN/AN/AHOOKHookipa PharmaN/AN/AN/AN/AN/APRQRProQR TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCBAYCymaBay TherapeuticsN/A10.9610.96CHMAChiasmaN/A7.917.08CNCEConcert PharmaceuticalsN/A9.039.03HOOKHookipa PharmaN/A3.503.50PRQRProQR Therapeutics0.103.543.54OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCBAYCymaBay Therapeutics95.03%CHMAChiasma61.68%CNCEConcert Pharmaceuticals70.63%HOOKHookipa Pharma63.88%PRQRProQR Therapeutics32.65%Insider OwnershipCompanyInsider OwnershipCBAYCymaBay Therapeutics7.00%CHMAChiasma8.30%CNCEConcert Pharmaceuticals11.33%HOOKHookipa Pharma5.82%PRQRProQR Therapeutics8.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableCHMAChiasma8557.89 millionN/ANot OptionableCNCEConcert Pharmaceuticals6447.94 million42.51 millionOptionableHOOKHookipa Pharma5698.95 million93.19 millionOptionablePRQRProQR Therapeutics15681.36 million74.52 millionOptionableCHMA, PRQR, CBAY, CNCE, and HOOK HeadlinesSourceHeadlineProQR Highlights Upcoming Presentations on Axiomer(TM) RNA Editing at ASGCT 27th Annual Meetingstockhouse.com - April 24 at 10:59 AMProQR defends RNA editing platform at EPOlifesciencesipreview.com - April 23 at 2:29 PMProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024globenewswire.com - April 23 at 7:00 AMComparing ProQR Therapeutics (NASDAQ:PRQR) & Teva Pharmaceutical Industries (NYSE:TEVA)americanbankingnews.com - April 23 at 1:44 AMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingfinance.yahoo.com - April 22 at 4:41 PMProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meetingglobenewswire.com - April 22 at 4:31 PMProQR retains key patent for RNA editing technologyuk.investing.com - April 21 at 10:34 PMProQR Achieves Successful Defense of New Challenge to its Axiomer(TM) IP Portfoliostockhouse.com - April 20 at 8:50 PMCitigroup Increases ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00americanbankingnews.com - April 20 at 4:50 AMProQR defends its Axiomer IP portfolio from new challengethepharmaletter.com - April 19 at 3:54 PMProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolioglobenewswire.com - April 19 at 7:00 AMProQR Therapeutics gets grant for oligonucleotide for reducing aberrant splice site selection in CEP290 genepharmaceutical-technology.com - April 18 at 1:28 PMCitigroup Raises ProQR Therapeutics (NASDAQ:PRQR) Price Target to $2.00marketbeat.com - April 18 at 12:13 PMProQR Therapeutics (NASDAQ:PRQR) Shares Pass Above Fifty Day Moving Average of $2.16americanbankingnews.com - April 16 at 3:56 AMProQR Therapeutics N.V. (PRQR)finance.yahoo.com - April 8 at 10:59 AMProQR Therapeutics (NASDAQ:PRQR) Given Consensus Recommendation of "Buy" by Analystsmarketbeat.com - March 29 at 2:14 AMBuy Rating Affirmed: ProQR’s Axiomer Platform Shows Promising Potential in CNS and Metabolic Disordersmarkets.businessinsider.com - March 14 at 7:10 PMBuy Rating Affirmed for ProQR on Strong Financials and Promising RNA Editing Platformmarkets.businessinsider.com - March 14 at 9:09 AMProQR Therapeutics Full Year 2023 Earnings: Misses Expectationsfinance.yahoo.com - March 14 at 9:09 AMProQR Announces Year End 2023 Operating and Financial Resultsglobenewswire.com - March 13 at 7:00 AMProQR Therapeutics gets grant for nucleic acid molecule for converting uridine to pseudouridinepharmaceutical-technology.com - March 5 at 10:34 AMPRQR Mar 2024 2.500 callfinance.yahoo.com - February 18 at 1:10 PMProQR Therapeutics N.V.wsj.com - February 16 at 8:41 AMProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editingfinance.yahoo.com - February 15 at 8:39 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.ChiasmaNASDAQ:CHMAChiasma, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing oral medications using transient permeability enhancer technology platform for the treatment of rare and serious chronic disease worldwide. The company offers MYCAPSSA, an oral octreotide capsule for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide. It also develops MPOWERED, an oral octreotide capsule, which has completed Phase III clinical trials for the maintenance treatment of adult patients with acromegaly. Chiasma, Inc. was incorporated in 2001 and is headquartered in Needham, Massachusetts.Concert PharmaceuticalsNASDAQ:CNCEConcert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.Hookipa PharmaNASDAQ:HOOKHOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.ProQR TherapeuticsNASDAQ:PRQRProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.